Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Consensus Target Price of $110.91

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been given an average rating of “Moderate Buy” by the sixteen brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $110.91.

Several research firms have issued reports on GPCR. Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen lowered shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Citizens Jmp reaffirmed a “market outperform” rating and set a $110.00 price target on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $21.19 on Wednesday. The stock has a 50 day simple moving average of $36.46 and a 200-day simple moving average of $42.96. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -21.19 and a beta of -1.30. Structure Therapeutics has a 12-month low of $20.73 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities analysts forecast that Structure Therapeutics will post -1.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GPCR. Assetmark Inc. increased its holdings in Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after purchasing an additional 449 shares in the last quarter. TrueMark Investments LLC boosted its position in shares of Structure Therapeutics by 1.4% in the first quarter. TrueMark Investments LLC now owns 34,377 shares of the company’s stock worth $1,657,000 after buying an additional 484 shares during the period. Sterling Capital Management LLC purchased a new stake in shares of Structure Therapeutics in the first quarter worth about $28,000. IFP Advisors Inc purchased a new stake in shares of Structure Therapeutics in the second quarter worth about $46,000. Finally, Cetera Investment Advisers grew its stake in shares of Structure Therapeutics by 17.0% in the first quarter. Cetera Investment Advisers now owns 7,720 shares of the company’s stock valued at $372,000 after buying an additional 1,124 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.